None

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physi...

Bayer to Present Data on Investigational Pulmonary Hypertension Compound at CHEST 2012

WAYNE, N.J., Oct. 17, 2012 /PRNewswire/ -- Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scien...

Bayer to Present Data on Investigational Pulmonary Hypertension Compound Riociguat at ATS 2013

WAYNE, N.J., May 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific for...

The S.E.R. Institute has Recently Added the Revolutionary Brainwave Optimization Technology to Their Alternative Health Services Together With Brain Training Centers

By integrating this recently patented technology into our process we hope to help people improve and optimize their thinking, their health, and their lives. Miami, Florida (PRWEB) October 11, 2012 Th...

Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

WAYNE, N.J., Feb. 11, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval...

Bayer's Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and gr...

ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC

RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of th...

Riociguat (BAY 63-2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study.

Riociguat (BAY 63-2521) and warfarin are likely to be used concomitantly to treat pulmonary hypertension. The aim of this double-blind, crossover, clinical pharmacological study in 30 healthy voluntee...

New treatment options for panic disorder: clinical trials from 2000 to 2010.

Introduction: Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk o...

Multifaceted approach to analyzing the pathogenesis of cardiovascular disease.

Heart failure is a common clinical feature of advanced cardiovascular disease that carries a high mortality risk. This review focuses on my journey seeking to understand the pathogenesis of heart fail...

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy.

Background: Use of aromatase inhibitors in women with postmenopausal breast cancer accompanies risks of bone loss. We evaluated changes in bone mineral density (BMD) and bone turnover markers in patie...

Posterior Cricoid Region Fluoroscopic Findings: The Posterior Cricoid Plication.

The region posterior to the cricoid cartilage is challenging to assess fluoroscopically. The purpose of this investigation is to critically evaluate the posterior cricoid (PC) region on fluoroscopy an...